Insider · CIK 0002064985
Jeffrey Leroy Larson
Files at TVRD (Tvardi Therapeutics, Inc.). First filing -, latest -.
Jeffrey Leroy Larson files SEC Form 4 as officer at TVRD (Tvardi Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey Leroy Larson has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 17, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +10,820 | $0.00 | $0 | 10,820 | Apr 21, 2025 |
| Apr 15, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +16,764 | - | - | 16,764 | Apr 17, 2025 |
| Apr 15, 2025 | TVRD Tvardi Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +5,364 | - | - | 5,364 | Apr 17, 2025 |
Questions about Jeffrey Leroy Larson
Answered from the filings on this page, as of the latest one.
Is Jeffrey Leroy Larson buying or selling?
Jeffrey Leroy Larson has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey Leroy Larson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey Leroy Larson has 0.
Where does Jeffrey Leroy Larson file Form 4?
Jeffrey Leroy Larson has filed Form 4 at TVRD (Tvardi Therapeutics, Inc.) as SVP, Research & Development. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.